Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 1/20 | 0.55 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.55 |
| ▸ | ATR | Q13535 | 10/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.49 |
| ▸ | PRKDC | P78527 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376748 | 0.90 | ACVR2A (0.55) | ACVR2ATGFBR2DGAT1ATRACVR1 | |
| SCHEMBL2258528 | 0.83 | DGAT1 (0.78) | DGAT1 | |
| SCHEMBL2258532 | 0.83 | DGAT1 (0.78) | DGAT1 | |
| Hydrochloric Acid SCHEMBL2255383 | 0.83 | DGAT1 (0.77) | DGAT1 | |
| Hydrochloric Acid SCHEMBL2255386 | 0.83 | DGAT1 (0.77) | DGAT1 | |
| SCHEMBL5537539 | 0.78 | DGAT1 (0.61) | ACVR2ATGFBR2DGAT1 | |
| SCHEMBL27991674 | 0.77 | HPGDS (0.47) | DGAT1DHODHKDM4EGLAHTT | |
| SCHEMBL18895999 | 0.76 | ATR (0.64) | ACVR2ATGFBR2ATRACVR1PRKDC | |
| SCHEMBL3462610 | 0.76 | ATR (0.63) | ATRPRKDCATM | |
| SCHEMBL28049139 | 0.76 | ATR (0.64) | ACVR2ATGFBR2ATRACVR1PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | ACVR2A 3271/4885TGFBR2 3744/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.